Quality Approval Sample Clauses

Quality Approval. The styles, designs, packaging, contents, workmanship and quality of all Articles, as well as all advertising and promotional materials relating thereto, and the specific media in which they shall be disseminated, must be approved by the Company in accordance with Section 6.1 hereof prior to any distribution, sale or other use thereof. Any other provision of this Agreement notwithstanding, the Company at all times shall have the right to take all actions which it reasonably deems necessary to ensure that: (a) Articles manufactured or sold hereunder, and the advertising and promotion of such Articles, are consistent with the reputation and prestige of the applicable Licensed Mxxx and (b) Articles are manufactured, distributed, sold and promoted by the Licensee in accordance with this Agreement, provided that, to the extent commercially practicable, prior to taking such action, the Company shall provide Licensee with an opportunity to take corrective action.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Quality Approval. After the Auto Design has been incorporated into a Simulator but before the Simulator is commercially distributed or displayed, Company will submit photographs of the Simulator to Licensor for a quality control review. Licensor shall have the opportunity to review the Simulator photographs for ten (10) business days and submit any suggested changes or improvements in the reproduction of the Auto Design to Company by the end of this period. Where reasonably possible, and considering production schedules and technical limitations, Company shall incorporate these changes and improvements in the final Simulator. Licensor's failure, within the ten (10) day period, to either (i) approve the reproduction of the Auto Design in the Simulator or (ii) submit suggestions shall be deemed to be approval of the reproduction of the Auto Design. With the exception of the foregoing, Licensor retains final approval of the reproduction of the Auto Design on a Simulator, which shall not be unreasonably withheld.
Sample 1
Quality Approval. The acceptance criteria for Biospecimens are set forth in Exhibit F.
Sample 1
Quality Approval. Before selling or distributing any of the Products not purchased from inventory or previously approved in license agreements in effect before the Effective Date of this Agreement, Licensee shall submit to Licensor free of cost, for its written approval, samples of (a) artwork and prototypes and production samples of products in each of the various categories; (b) samples of finished product, including packaged samples, in each of the various categories; (c) samples of finished cartons, labels, containers, packing and wrapping materials in each of the various categories; and (d) samples of advertising and promotional copy in each of the various categories (herein referred to as “Samples”). Licensor shall then have the right to approve or disapprove of such Samples within fifteen (15) business days of such submission, such approval not to be unreasonably withheld, with the failure to disapprove in writing within said fifteen (15) business day period to constitute an approval by Licensor. Disapprovals shall be accompanied by a written explanation of any and all deficiencies and the changes necessary to secure approval. Licensor hereby approves of Licensee’s continued use during the Term of this Agreement of all Samples in use by Licensee or Licensor, or any third party licensees of Licensor, as of the Effective Date of this Agreement.
Sample 1

Related to Quality Approval

  • APPROVAL OF PLANS AND SPECIFICATIONS The Plans and Specifications will conform to the requirements and conditions set out by applicable law or any effective restrictive covenant, and to all governmental authorities which exercise jurisdiction over the Leased Premises or the construction thereon.

  • Requisite Regulatory Approvals All Consents required to be obtained from or made with any Governmental Authority in order to consummate the transactions contemplated by this Agreement shall have been obtained or made.

  • Authority; Approval Seller has full corporate or other organizational power and authority to execute and deliver each of the Transaction Documents to which it is or will be a party, to perform its obligations thereunder and to consummate the Transaction. The execution, delivery and performance of this Agreement by Seller and the consummation of the Transaction by Seller has been duly and validly authorized by all necessary corporate action on the part of Seller. The execution, delivery and performance of each of the Ancillary Agreements to which Seller is or will be a party has been, or at the Closing will be, duly and validly authorized by all necessary corporate or other action on the part of such Person. No vote or consent of Seller’s stockholders is required to approve and authorize the consummation by Seller of the Transaction. This Agreement has been, and each of the Ancillary Agreements will be at Closing, duly executed and delivered by Seller and, when executed and delivered by Buyer and the other parties thereto, will constitute a valid and binding agreement of Seller, enforceable against Seller in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, preferential transfer, reorganization, moratorium and similar Laws relating to or affecting creditors’ rights generally and subject, as to enforceability, to the effect of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) (the “Bankruptcy and Equity Exception”).

  • Regulatory Approval Any waiting period applicable to the Transactions under the HSR Act shall have been terminated or shall have expired.

  • No Regulatory Approval By the Company or Parent, if its Board of Directors so determines by a vote of a majority of the members of its entire Board, in the event any Requisite Regulatory Approval shall have been denied by final, nonappealable action by such Governmental Authority or a Governmental Authority shall have requested the permanent withdrawal of an application therefor.

  • Approval of Plans Landlord will not check Tenant drawings for building code compliance. Approval of the Final Plans by Landlord is not a representation that the drawings are in compliance with the requirements of governing authorities, and it shall be Tenant’s responsibility to meet and comply with all federal, state, and local code requirements. Approval of the Final Plans does not constitute assumption of responsibility by Landlord or its architect for their accuracy, sufficiency or efficiency, and Tenant shall be solely responsible for such matters.

  • Marketing Plans 1. The MCO shall develop a marketing plan that meets SDOH guidelines and any local requirements as approved by the State Department of Health (SDOH).

  • Regulatory Approvals All Requisite Regulatory Approvals shall have been obtained and shall remain in full force and effect and all statutory waiting periods in respect thereof shall have expired, and no such Requisite Regulatory Approval shall have resulted in the imposition of any Materially Burdensome Regulatory Condition.

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Agency Approval The Servicer has been approved by FNMA or FHLMC and will remain approved as an "eligible seller/servicer" of conventional, residential mortgage loans as provided in FNMA or FHLMC guidelines and in good standing. The Servicer has not received any notification from FNMA or FHLMC that the Servicer is not in compliance with the requirements of the approved seller/servicer status or that such agencies have threatened the servicer with revocation of its approved seller/servicer status.

Time is Money Join Law Insider Premium to draft better contracts faster.